PRESS RELEASE published on 10/30/2025 at 07:30, 11 months 30 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 1 year ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
BRIEF published on 09/29/2025 at 23:05, 1 year ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 1 year ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 23:00, 1 year ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie résultats financiers du premier semestre 2025 : gestion optimisée de trésorerie, financement post-clôture, transfert de fabrication, protocole d'étude soumis à l'ANSM Résultats Financiers Financement Trésorerie GenSight Biologics Étude ANSM
BRIEF published on 08/28/2025 at 20:05, 1 year 2 months ago GenSight Biologics reporte la publication de ses résultats financiers semestriels 2025 Résultats Financiers Conformité Réglementaire Report GenSight Biologics Procédures D'audit
BRIEF published on 08/28/2025 at 20:05, 1 year 2 months ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 1 year 2 months ago Informations privilégiées / Autres communiqués GenSight Biologics reporte la publication de ses résultats financiers semestriels 2025. Le report est dû à l'audit en cours, non lié à des problèmes financiers. Réunions importantes reprogrammées Résultats Financiers Communication Financière Audit Report GenSight Biologics
PRESS RELEASE published on 08/28/2025 at 20:00, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
Published on 10/29/2026 at 08:00, 22 minutes ago Touchstone Exploration Provides an Operational Update
Published on 10/29/2026 at 07:30, 52 minutes ago Tocvan Pilot Mine Trench at Gran Pilar Averages 4.6 g/t Au With Samples Up to 24.4 g/t Au; New Zone 1.3 km East Returns Up to 234 g/t Ag
Published on 10/28/2026 at 22:35, 9 hours 47 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 19 hours 52 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 19 hours 52 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/29/2026 at 08:00, 21 minutes ago EQS-Adhoc: Henkel AG & Co. KGaA: Henkel achieves very strong organic sales growth in the third quarter and updates outlook for 2026
Published on 10/29/2026 at 08:00, 22 minutes ago Aquis Stock Exchange: Application for admission to trading
Published on 10/29/2026 at 07:20, 1 hour 2 minutes ago Q3 2026: Air Liquide accelerates, driven by sales growth and the launch of its strategic plan
Published on 10/29/2026 at 07:20, 1 hour 2 minutes ago T3 2026 : Air Liquide accélère, porté par des ventes en croissance et le lancement de son plan stratégique
